汉森制药
(002412)
| 流通市值：31.66亿 | | | 总市值：32.00亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 693,981,713.71 | 480,445,782.48 | 254,032,546.62 | 955,530,797.42 |
| 营业收入 | 693,981,713.71 | 480,445,782.48 | 254,032,546.62 | 955,530,797.42 |
| 二、营业总成本 | 554,722,346.7 | 379,976,886.84 | 193,715,774.24 | 784,243,656.89 |
| 营业成本 | 172,562,813.76 | 121,991,256.39 | 65,445,562.67 | 255,894,194.21 |
| 税金及附加 | 13,963,958.48 | 9,580,968.74 | 5,206,000.87 | 18,908,795.3 |
| 销售费用 | 294,411,101.54 | 200,756,658.29 | 102,553,717.54 | 394,683,252.87 |
| 管理费用 | 45,119,863.61 | 27,595,557.35 | 12,213,898.68 | 68,357,240.5 |
| 研发费用 | 27,453,358.32 | 19,134,281.51 | 7,885,856.79 | 44,479,163.31 |
| 财务费用 | 1,211,250.99 | 918,164.56 | 410,737.69 | 1,921,010.7 |
| 其中:利息费用 | 2,023,105.59 | 1,492,700.03 | 901,798.65 | 3,679,861.14 |
| 其中:利息收入 | 1,082,521.94 | 770,518.44 | 520,201.69 | 1,972,717.28 |
| 加:公允价值变动收益 | 1,396,878.66 | 807,990.85 | 369,158.95 | 1,796,009.27 |
| 加:投资收益 | 4,740,181.17 | 11,810,076.16 | 4,586,980.33 | 61,149,887.87 |
| 资产处置收益 | - | - | - | -15,434.98 |
| 资产减值损失(新) | -6,633.7 | 9,869.17 | 24,309.42 | -372,957.08 |
| 信用减值损失(新) | -1,713,877.95 | -1,787,330.39 | -20,720.83 | -3,284,797.37 |
| 其他收益 | 6,039,093.28 | 4,497,648.58 | 2,734,062.59 | 4,377,487.07 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 149,715,008.47 | 115,807,150.01 | 68,010,562.84 | 234,937,335.31 |
| 加:营业外收入 | 452,520.53 | 322,504.64 | 33,716.63 | 625,379.16 |
| 减:营业外支出 | 612,256.34 | 262,329.35 | 107,150.33 | 9,545,441.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 149,555,272.66 | 115,867,325.3 | 67,937,129.14 | 226,017,272.53 |
| 减:所得税费用 | 18,802,226.68 | 15,373,326.94 | 9,672,454.97 | 21,002,388.75 |
| 六、净利润 | 130,753,045.98 | 100,493,998.36 | 58,264,674.17 | 205,014,883.78 |
| 持续经营净利润 | 130,753,045.98 | 100,493,998.36 | 58,264,674.17 | 205,014,883.78 |
| 归属于母公司股东的净利润 | 130,753,045.98 | 100,493,998.36 | 58,264,674.17 | 205,014,883.78 |
| (一)基本每股收益 | 0.26 | 0.2 | 0.12 | 0.41 |
| (二)稀释每股收益 | 0.26 | 0.2 | 0.12 | 0.41 |
| 八、其他综合收益 | 7,490,193.67 | 14,068,081.35 | 6,133,860.08 | 14,842,351.97 |
| 归属于母公司股东的其他综合收益 | 7,490,193.67 | 14,068,081.35 | 6,133,860.08 | 14,842,351.97 |
| 九、综合收益总额 | 138,243,239.65 | 114,562,079.71 | 64,398,534.25 | 219,857,235.75 |
| 归属于母公司股东的综合收益总额 | 138,243,239.65 | 114,562,079.71 | 64,398,534.25 | 219,857,235.75 |
| 公告日期 | 2024-10-29 | 2024-08-14 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |